About this event
Cell therapies present unprecedented therapeutic potential to treat and even cure a wide range of diseases. However, key challenges remain to manufacturing safe and compliant cell therapy products. Like with all biologics, formulation, stability, and purity for cell therapy products is essential to reduce immunogenic risks, ensure long lasting products and enable uninterrupted administration. In this webinar, our CSO and co-founder Bernardo Cordovez, PhD, explains how Aura+ enables complete product purity characterization by imaging, counting, and identifying cells and particle impurities in cell products. Specifically, this webinar focuses on cell counting, viability, aggregate characterization and measuring residual Dynabeads™️.
About the speaker
Dr. Bernardo Cordovez is Co-Founder and Chief Scientific officer of Halo Labs, leading the company’s research and development. Prior to starting Halo Labs, Bernardo was a Postdoctoral Associate at Cornell University, where he also obtained his M.S. and Ph.D. His wide range of technical experience includes particle analysis, detection and manipulation, drug delivery devices, microfluidics, photonics and bioenergy production.
Hosted by
-
Team member
Devon Nemelka Marketing Specialist @ Halo LabsDN T
-
Team member
Steven Le Director of Marketing @ Halo LabsSL T
Halo Labs
The Aura® instruments have you covered for all of your aggregate and particle analysis needs. High-throughput particle count, size, and ID.
